Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

News SummaryMost relevantAll newsSector newsTweets

Roche Holding Ltd. : UPCOMING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Roche Holding AG and Reminds Investors with Losses to Contact the Firm

share with twitter share with LinkedIn share with facebook
share via e-mail
07/17/2017 | 10:03pm CEST

IRVINE, CA / ACCESSWIRE / July 17, 2017 / Khang & Khang LLP (the "Firm") announces a securities class action lawsuit against Roche Holding AG ("Roche Holding" or the "Company") (OTCQX: RHHBY). Investors, who purchased or otherwise acquired shares from March 2, 2017 through June 5, 2017, inclusive (the "Class Period"), are encouraged to contact the Firm before the August 7, 2017 lead plaintiff motion deadline.

If you purchased shares of Roche Holding during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone at (949) 419-3834, or by e-mail at [email protected].

There has been no class certification in this case yet, and until certification occurs, you are not represented by an attorney. You may also choose to take no action and remain a passive class member.

According to the Complaint, throughout the Class Period, Roche Holding issued materially false and misleading statements and/or failed to disclose material information, specifically that the combination of the Company's breast cancer drug, Perjeta, and its older treatment, Herceptin, is only marginally more effective than Herceptin alone in preventing breast cancer, and has a higher rate of side effects. Following this news, Roche Holding's stock price dropped materially, causing investors harm according to the Complaint.

If you want to learn more about this lawsuit, or if you have questions about this notice or your rights, please contact Joon M. Khang, a prominent litigator for nearly two decades, by telephone at (949) 419-3834, or by e-mail at [email protected].

This press release may constitute Attorney Advertising in some jurisdictions.


Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
[email protected]

SOURCE: Khang & Khang LLP

© Accesswire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ROCHE HOLDING LTD.
09/22 ROCHE : receives EU approval of TECENTRIQ® (atezolizumab) in a specific type of ..
09/22 ROCHE : unloads another plant in deal with Recipharm that saves 200 jobs
09/22 ROCHE : receives EU approval of Gazyvaro for people with previously untreated ad..
09/22 ROCHE : receives European approval for Actemra /RoActemra in giant cell arteriti..
09/21 HALOZYME THERAPEUTICS : Licenses New Enhanze Target For $30 Million Upfront Paym..
09/21 ROCHE : Best way to counter Diabetes is Healthy Diet, Exercise and constant moni..
09/21 ROCHE : Spanish plant becomes eighth solid dose site for Recipharm
09/21 ROCHE : Invitation to Roche's 9 Months Sales 2017 Audio Webcast and Conference C..
09/20 ABBVIE : and Roche plan Venclexta combo filings in leukaemia
09/20 ROCHE : FDA locks down combo immunotherapy trials, Roche added to hold
More news
News from SeekingAlpha
09/22 Expanded use of Roche's Gazyvaro OK'd in Europe
09/22 Roche's Actemra/RoActemra OK'd in Europe for giant cell arteritis
09/21 FDA's Woodcock says clinical trials system "broken"
09/20 Daily OTC Markets Round-Up - 9/19/2017
09/19 YOUR DAILY PHARMA SCOOP : Nabriva's Further Potential, Allergan's IP Gimmick, Su..
Financials ( CHF)
Sales 2017 53 361 M
EBIT 2017 18 314 M
Net income 2017 11 181 M
Debt 2017 8 848 M
Yield 2017 3,46%
P/E ratio 2017 18,52
P/E ratio 2018 16,86
EV / Sales 2017 4,17x
EV / Sales 2018 3,93x
Capitalization 214 B
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 277  CHF
Spread / Average Target 12%
EPS Revisions
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.6.19%220 358
JOHNSON & JOHNSON15.63%353 617
NOVARTIS11.88%223 850
PFIZER10.81%214 206
MERCK AND COMPANY11.75%178 914
SANOFI9.06%126 655